Eptinezumab Efficacy Confirmed in Asian Chronic Migraine Patients from Phase III Trial Results A recent trial shows that Eptinezumab effectively reduces monthly migraine days in the Asian population, crucial in addressing unmet healthcare needs.

Eptinezumab Efficacy Confirmed in Asian Chronic Migraine Patients from Phase III Trial Results #Denmark #Valby #Vyepti #Eptinezumab #SUNRISE_Trial